Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tettero, Jesse M., Al-Badri, Waleed K. W., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., van Elssen, Catharina H. M. J., Fischer, Thomas, Gjertsen, Bjorn T., van Gorkom, Gwendolyn N. Y., Gradowska, Patrycja, Greuter, Marjolein J. E., Griskevicius, Laimonas, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G., Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Löwenberg, Bob, Ossenkoppele, Gert J., Janssen, Jeroen J. W. M., Cloos, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589259/
https://www.ncbi.nlm.nih.gov/pubmed/36300090
http://dx.doi.org/10.3389/fonc.2022.999822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589259/
https://www.ncbi.nlm.nih.gov/pubmed/36300090
http://dx.doi.org/10.3389/fonc.2022.999822

Ejemplares similares